In Poland, children aged 5-11 are being vaccinated against coronavirus Vaccination against coronavirus in children aged 5-11 starts in Poland on December 16. According to European Truth, RMF24 reports.
A child can be vaccinated as soon as they are 5 years old. Injections will be given at the same interval as for adults – 21 days. Children who have serious problems with the immune system will be offered three doses – the third booster 28 days after the second.
It will be recalled that on November 25, the European Medicines Agency (EMA) recommended the use of Comirnaty coronavirus vaccine from BioNTech-Pfizer for children aged 5-11. It is recommended to use a lower dose than for older groups – 10 mcg instead of 30 mcg. In all other respects, the procedure is recommended to remain the same: two doses with an interval of 21 days.
Some EU countries have already started vaccinating this group, and some will start vaccination in the near future. Yes, the campaign started in the Czech Republic on Monday, and this week Italy will start vaccinating children aged 5-11.
The EU regulator has approved the use of BioNTech-Pfizer for children aged 5-11 The European Medicines Agency (EMA) has recommended the use of Comirnaty coronavirus vaccine from BioNTech-Pfizer for children aged 5-11 years.
According to European Truth, the EMA issued a statement on November 25.
The EMA’s Committee on Medicinal Products for Human Use has recommended expanding the use of the vaccine and allowing it to be given to children over 5 years of age. For vaccination of children 5-11 years it is recommended to use a lower dose than for the previous two groups – 10 mcg instead of 30 mcg. In all other respects, the procedure is recommended to remain the same: two doses with an interval of 21 days.
The EMA notes that a main study in children aged 5-11 years confirmed that vaccination with a reduced dose of 10 mcg gave an immune system response similar to that of a standard dose of 30 mcg in older groups.
Efficacy was tested in a group of almost 2,000 children aged 5-11 years who had no signs of infection at the time of the trial. Of the 1,305 children who received the real vaccine, three became ill, compared with 16 of the 663 children who received placebo. Accordingly, the vaccine in this study showed a 90.7% effectiveness in protecting against the disease with symptoms.